ATR kinase inhibitor AZD6738

From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor AZD6738 selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.

Learn more about ATR kinase inhibitor AZD6738

Latest research - ATR kinase inhibitor AZD6738

Clinical trials

External links

Medicine icon
Medicine icon

This WikiMD article ATR kinase inhibitor AZD6738 is a stub. If you are familiar with the topic ATR kinase inhibitor AZD6738, you can help us. Paid editors welcome!


ATR kinase inhibitor AZD6738 is part of WikiMD's free ^articles!

^ATR kinase inhibitor AZD6738 (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available